Disease progression modelling from preclinical Alzheimer’s disease (AD) to AD dementia

To characterize the course of Alzheimer’s disease (AD) over a longer time interval, we aimed to construct a disease course model for the entire span of the disease using two separate cohorts ranging from preclinical AD to AD dementia. We modelled the progression course of 436 patients with AD contin...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Scientific reports 2021-02, Vol.11 (1), p.4168-10, Article 4168
Hauptverfasser: Cho, Soo Hyun, Woo, Sookyoung, Kim, Changsoo, Kim, Hee Jin, Jang, Hyemin, Kim, Byeong C., Kim, Si Eun, Kim, Seung Joo, Kim, Jun Pyo, Jung, Young Hee, Lockhart, Samuel, Ossenkoppele, Rik, Landau, Susan, Na, Duk L., Weiner, Michael, Kim, Seonwoo, Seo, Sang Won
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:To characterize the course of Alzheimer’s disease (AD) over a longer time interval, we aimed to construct a disease course model for the entire span of the disease using two separate cohorts ranging from preclinical AD to AD dementia. We modelled the progression course of 436 patients with AD continuum and investigated the effects of apolipoprotein E ε4 (APOE ε4) and sex on disease progression. To develop a model of progression from preclinical AD to AD dementia, we estimated Alzheimer’s Disease Assessment Scale-Cognitive Subscale 13 (ADAS-cog 13) scores. When calculated as the median of ADAS-cog 13 scores for each cohort, the estimated time from preclinical AD to MCI due to AD was 7.8 years and preclinical AD to AD dementia was 15.2 years. ADAS-cog 13 scores deteriorated most rapidly in women APOE ε4 carriers and most slowly in men APOE ε4 non-carriers ( p  
ISSN:2045-2322
2045-2322
DOI:10.1038/s41598-021-83585-3